Citadel Advisors
URGN icon

Citadel Advisors’s UroGen Pharma URGN Stock Holding History

Citadel Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$592K Buy
32,900
+4,400
+15% +$88.2K ﹤0.01% 8888
2025
Q4 		$667K Sell
28,500
-67,800
-70% -$1.47M ﹤0.01% 8313
2025
Q3 		$1.92M Sell
96,300
-180,200
-65% -$3.24M ﹤0.01% 6151
2025
Q2 		$3.79M Buy
276,500
+267,200
+2,873% +$2.56M ﹤0.01% 4580
2025
Q1 		$103K Sell
9,300
-500
-5% -$5.33K ﹤0.01% 11416
2024
Q4 		$104K Sell
9,800
-39,400
-80% -$472K ﹤0.01% 11428
2024
Q3 		$625K Buy
49,200
+13,900
+39% +$206K ﹤0.01% 7792
2024
Q2 		$592K Buy
35,300
+17,900
+103% +$255K ﹤0.01% 7704
2024
Q1 		$261K Buy
17,400
+1,300
+8% +$21.2K ﹤0.01% 9772
2023
Q4 		$242K Buy
16,100
+8,000
+99% +$104K ﹤0.01% 9589
2023
Q3 		$113K Sell
8,100
-5,200
-39% -$83.5K ﹤0.01% 10730
2023
Q2 		$138K Buy
13,300
+1,800
+16% +$19.9K ﹤0.01% 10454
2023
Q1 		$106K Buy
11,500
+11,100
+2,775% +$102K ﹤0.01% 11173
2022
Q4 		$3.55K Buy
+400
New +$3.79K ﹤0.01% 14198
2021
Q4 		– Sell
-35,500
Closed -$597K – 14796
2021
Q3 		$597K Sell
35,500
-500
-1% -$7.92K ﹤0.01% 9430
2021
Q2 		$550K Buy
+36,000
New +$651K ﹤0.01% 9863
2021
Q1 		– Sell
-22,300
Closed -$402K – 13737
2020
Q4 		$402K Buy
+22,300
New +$467K ﹤0.01% 8561
2020
Q3 		– Sell
-10,900
Closed -$285K – 10768
2020
Q2 		$285K Sell
10,900
-56,200
-84% -$1.37M ﹤0.01% 7991
2020
Q1 		$1.2M Sell
67,100
-1,600
-2% -$43.2K ﹤0.01% 5005
2019
Q4 		$2.29M Buy
+68,700
New +$1.88M ﹤0.01% 4190

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Citadel Advisors's URGN Position: Q1 2026 in Review

Citadel Advisors reduced its UroGen Pharma (URGN) stake by 64% in Q1 2026, selling an estimated $9.42M and leaving 267,996 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #4400.

Citadel Advisors first reported a position in URGN in Q1 2018 and has held it in 30 quarters since. The position peaked at $17.7M in Q3 2018. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Citadel Advisors held 267,996 shares of UroGen Pharma worth $4.82M as of Q1 2026.
  • Citadel Advisors sold 469,761 UroGen Pharma shares in Q1 2026, an estimated $9.42M.
  • UroGen Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4400 holding.
  • Citadel Advisors first reported a position in UroGen Pharma in Q1 2018 and has held it in 30 quarters since.
  • Citadel Advisors's UroGen Pharma position peaked at $17.7M in Q3 2018.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.